Acute effects of the sodium glucose transporter (SGLT) -2 inhibitors, Dapagliflozin, on Hemorheology, Leukocyte Activation and Oxidative Stress in type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Nov 2016 New trial record